AllianceBernstein’s Structure Therapeutics GPCR Stock Holding History

AllianceBernstein’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.5M	Sell	611,708 -27,105	-4%	-$1.2M	0.01%	789
2026 Q1	$44.4M	Sell	638,813 -210,038	-25%	-$14.4M	0.01%	641
2025 Q4	$59M	Buy	848,851 +819,292	+2,772%	+$33.5M	0.02%	573
2025 Q3	$828K	Buy	29,559 +7,060	+31%	+$141K	﹤0.01%	2436
2025 Q2	$467K	Buy	+22,499	New	+$495K	﹤0.01%	2681
2025 Q1	–	Sell	-142,825	Closed	-$3.87M	–	3210
2024 Q4	$3.87M	Sell	142,825 -16,372	-10%	-$581K	﹤0.01%	1609
2024 Q3	$6.99M	Buy	159,197 +110,549	+227%	+$4.27M	﹤0.01%	1366
2024 Q2	$1.91M	Buy	+48,648	New	+$2M	﹤0.01%	1982

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AllianceBernstein's GPCR Position: Q2 2026 in Review

AllianceBernstein reduced its Structure Therapeutics (GPCR) stake by 4.2% in Q2 2026, selling an estimated $1.2M and leaving 611,708 shares worth $29.5M. The position accounts for 0.01% of the portfolio, ranked #789.

AllianceBernstein first reported a position in GPCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $59M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

AllianceBernstein held 611,708 shares of Structure Therapeutics worth $29.5M as of Q2 2026.
AllianceBernstein sold 27,105 Structure Therapeutics shares in Q2 2026, an estimated $1.2M.
Structure Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #789 holding.
AllianceBernstein first reported a position in Structure Therapeutics in Q2 2024 and has held it in 8 quarters since.
AllianceBernstein's Structure Therapeutics position peaked at $59M in Q4 2025.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.